

A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

NCT06760208

Status RECRUITING
Sponsor Pfizer
Enrollment 660 participants

Key Eligibility Criteria

Inclusion (3)

- Infant, children and adolescents who are aged 6 weeks to under 18 years or adult who are 18 years or older
- Subjects who have been prescribed Prevenar 20 by their physician as per approved product label
- Evidence of a personally signed and dated informed consent document indicating that the subject or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study

Exclusion (3)

- Subjects meeting any of the following criteria will not be included in the study:
- Subjects with contraindication according to approved label of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine)
- Any subjects (or a legally acceptable representative) who do not agree that Pfizer and companies working with Pfizer use his/her information

Locations (1 total)

Pfizer Korea, Seoul, South Korea